An observational analysis using target trial emulation suggests that initiating vasopressin very early in septic shock—within three hours of norepinephrine escalation—may reduce 28-day mortality. The report described an ultra-early group showing an estimated 5% absolute mortality reduction versus a slightly delayed early group. However, accompanying editorial commentary emphasized that no randomized controlled trial has yet confirmed mortality benefit from the strategy. The study adds weight to the idea that timing of vasopressor initiation—not just choice—can matter in critical care. The result could influence how clinicians interpret timing questions while reinforcing the need for prospective randomized validation.